Management of viral hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue SUPPL. 1, 2002, Pages

  Pramoolsinsup, Chutima ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Chronic liver disease; Hepatitis B virus; Interferon; Nucleoside analog

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; AMDOXOVIR; AMINOTRANSFERASE; ANTIVIRUS AGENT; BETA INTERFERON; CLEVUDINE; DNA VACCINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; GANCICLOVIR; GENHEVAC; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 12; LAMIVUDINE; LOBUCAVIR; MUTANT PROTEIN; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NUCLEOSIDE ANALOG; PREDNISOLONE; RNA DIRECTED DNA POLYMERASE; THYMOSIN ALPHA; UNCLASSIFIED DRUG; VIDARABINE PHOSPHATE; VIRUS DNA;

CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; CROSS RESISTANCE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOMODULATION; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; META ANALYSIS; MUTATION; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN MOTIF; RECURRENT INFECTION; SEROCONVERSION; SIDE EFFECT; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS REPLICATION; WILD TYPE;

EID: 0036098865     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.17.s1.3.x     Document Type: Conference Paper

References (147)

1. Control of hepatitis B by immunization: Global perspective
2. Epidemiology of hepatitis B virus infection in the Asia-Pacific region
3. Natural history of chronic hepatitis B virus infection
4. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B
5. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma
6. Natural history of chronic HBV infection
7. Natural history of hepatitis B virus infection in children
8. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus
9. Coinfections with hepatitis G and/or C virus in hepatitis B-related chronic liver disease
10. Acute hepatitis A and acquired immunity to hepatitis A virus (HBV) carriers and in HBV- or hepatitis C virus-related chronic liver diseases in Thailand
11. Clinical and virologival course of chronic hepatitis B virus infection with hepatitis C and D virus markers
12. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection
13. Effect of interferon-α on hepatits B viral antigen expression in primary hepatocyte culture
14. Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B
15. Predisolone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis
16. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
17. Prednisolone-interferon combination in the treatment of chronic hepatitits B direct and indirect meta-analysis
18. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen-negative chronic hepatitis B
19. Low-dose, titratable interferon alpha in decompensated liver disease caused by chronic infection with hepatitis B virus
20. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum
21. Long-term follow-up of chronic hepatitis B patients treated with interferon alpha
22. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B
23. Drug therapy. The treatment of chronic viral hepatitis
24. Rondomized, controlled trial of recombinant human α-IFN in patients with chronic hepatitis B
25. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
26. Current therapeutic trends in therapy for chronic viral hepatitis
27. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: A randomised controlled trial
28. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection
29. Long-term results with interferon therapy in chronic type B hepatitis: A prospective randomized trial
30. Long-term follow up of patients with chronic hepatitis B treated with inter-feron alpha
31. Long-term remission of chronic hepatitis B after alpha-interferon therapy
32. Antiviral therapy for the Asian patient with chronic hepatitis B
33. Hepatitis B virus precore/core variation and interferon therapy
34. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alpha
35. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study
36. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alpha-2a. The European Concerted Action on Viral Hepatitis (EUROHEP)
37. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials
38. The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection
39. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial
40. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation
41. Clinical pharmacokinetics of lamivudine
42. Lamivudine treatment can restore T-cell responsiveness in chronic hepatitis B
43. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomized trial
44. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
45. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years
46. Efficacy of long-tem lamivudine monotherapy in patients with hepatitis B e Antigen-negative chronic hepatitis B
47. Long-term therapy of chronic hepatitis B with lamivudine
48. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection
49. An open comparative study of lamivudine and famciclovir in the treatment of chronic hepatitis B infection
50. Lamivudine as intial treatment for chronic hepatitis B in the United States
51. Pretherapy alanine amino-transferase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
52. A one-year trial of lamivudine for chronic hepatitis B
53. Quantitative assessment of hepatitis B virus DNA during a 24-week course of lamivudine therapy
54. Characterization of the antiviral effects of 2′-carbodeoxy-guanosine in ducks chronically infected with duck hepatitis B virus
55. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy
56. Durable HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B
57. Seroconversion after lamivudine treatment is not durable in patients with chronic hepatitis B from Korea
58. Extended lamivudine retreatment for chronic hepatitis B. Maintenance of viral suppression after discontinuation of therapy
59. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy
60. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine
61. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine
62. Improvements in liver histology and cirrhosis with extended lamivudine therapy
63. Cost-effective analysis of lamivudine for the treatment of chronic hepatitis B
64. Lamivudine for suppression of viral replication in patients with decompensated chronic hepatitis B
65. Lamivudine for chronic delta hepatitis
66. Immunosuppression and reactivation of hepatitis B in the lamivudine era: Opportunities for prevention and exploitation?
67. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
68. Prevention of recurrent hepatitis B infection following liver transplantation: Experience in 112 North American patients
69. Lamivudine for suppression of viral replication in patients with decompensated chronic hepatitis B
70. End-stage liver disease and liver transplantation: Role of lamivudine therapy in patients with chronic hepatitis B
71. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
72. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation
73. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: Case report and review of the literature
74. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection
75. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy
76. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B
77. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
78. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
79. Genotypic resisance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: Incidence, kinetics of emergence, and correlation with disease parameters
80. Anti-HIV and anti-HBV activity and resistance profile of 2′-3′-dideoxy-3′-thiocyanate (3TC) and its arylphosphorami-date derivative CF 1109
81. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
82. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus
83. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
84. The polymerase L528M mutation cooperates with nucleotide binding-site muations increasing, hepatitis B virus replication and drug resistance
85. Replication fitness of hepatitis B virus polymerase mutants after antiviral treatment following liver transplantation
86. 20-Fold increase in risk of Lamivudine resistance in hepatitis B virus sub type adw
87. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
88. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B
89. Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation
90. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
91. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
92. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients
93. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
94. Continued histological improvement in Chinese patients with chronic hepatitis B with 2 years lamivudine
95. Interferon alpha therapy for chronic hepatitis B in children: A multinational randomized controlled trial
96. Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children
97. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient. Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immunoglobulin
98. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
99. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men
100. Interferon-alfa treatment of chronic hepatitis B. Randomized trial in a predominantly homosexual male population
101. Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population
102. Good results of lamivudine in hepatitis B surface antigen-positive patients with active viral replication before liver transplantation
103. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B
104. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
105. Hepatitis B virus and liver transplantation
106. Perspectives for the treatment of hepatitis B virus infections
107. Famciclovir in chronic hepatitis B. Results of a dose-finding study
108. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection
109. Clinical experience with famciclovir against hepatitis B virus
110. Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection
111. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation
112. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
113. Sensitivity of L-(-) 2, 3-dideoxy-thiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues
114. Adefovir dipivoxil
115. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
116. Loss of serum HBV-DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B. Two placebo controlled phase II studies
117. In vivo antiviral activity and pharmacokinetics of (-) -cis-5-fluoro-1-[(2-hydroxymethyl) -1, 3 oxathiolan-5-yl] cytosine in woodchuck hepatitis virus-infected woodchucks
118. Efficacy of the carbocylic2′-deoxyguanosine nucleoside BMS-200475 in the wood chuck model of hepatitis B virus infection
119. A randomized placebo-controlled study on the efficacy of 12 month famciclovir treatment in patients with chronic Hepatitis HBeAg + hepatitis B
120. Sustained antiviral efficacy in the woodchuck model of chronic hepatitis infection following long-term entecavir (BMS-200475) treatment
121. Two novel antiviral agents. DAPD and L-FMAU, which are active against wild type and lamivudine-resistant HBV
122. A phase 2 multi-center study of oral lobucavir for treatment of chronic hepatitis B
123. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients
124. Oral ganciclovir treatment in chronic hepatitis B virus infection: A pilot study
125. Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia wihtout producing significant side effects
126. Antiviral chemotherapy for the treatment of hepatitis B virus infection
127. Gene therapy for chronic viral hepatitis. Ribozymes, antisense oligounucleotides and dominant negative mutants
128. A randomized controlled trial of Thymosin alpha-1 versus interferon alpha treatment in patients with hepatitis B e antigen antibody and hepatitis B virus DNA-positive chronic hepatitis B
129. Efficacy of thymosin a1 in patients with chronic hepatitis B. A randomised, controlled trial
130. Thymosin alpha-1 treatment of chronic hepatitis B. Results of a phase III multicenter, randomized, placebo-controlled double blinded study
131. A randomized controlled study of thymosin-alpha 1 therapy in patients with antiHBe, HBV-DNA-positive chronic hepatitis B
132. Specific vaccine therapy in chronic hepatitis B. Induction of T-cell proliferative responses specific for envelope antigens
133. Phase 1 study of a potent adjuvanted hepatitis B vaccine (HBV/MF59) for therapy of chronic hepatitis B
134. Immunotherapy of chronic hepatitis B by anti-HBV vaccine
135. Induction of T helper cell type1 response and elimination of HBeAg during treatment with IL-12 in a patient with therapy-refractory chronic hepatitis B
136. Increment of recombinant HBAg-specific T-cell precursors after revaccination of slow responder children
137. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: A retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc
138. Clearance of HBsAg after bone marrow transplantation: Role of adoptive immunity transfer
139. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection
140. Hepatitis B associated liver failure following bone marrow transplantation
141. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B
142. Combination therapy for chronic hepatits B
143. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro
144. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: A viral dynamics study
145. Lamivudine for suppression of viral replication in patients with decompensated chronic hepatitis B
146. Core Working Party for the Asia-Pacific consensus on hepatitis B and C consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region